Taniborbactam

Summary

Taniborbactam (CHEMBL4594290) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including bacterial infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 389.3 Da · C19H28BN3O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594290
Name	Taniborbactam
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	76902493
Molecular formula	C19H28BN3O5
Molecular weight	389.3
InChIKey	PFZUWUXKQPRWAL-PXCJXSSVSA-N

SMILES: B1([C@H](CC2=C(O1)C(=CC=C2)C(=O)O)NC(=O)CC3CCC(CC3)NCCN)O

IUPAC name: (3R)-3-[[2-[4-(2-aminoethylamino)cyclohexyl]acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid

Also known as: Taniborbactam, Vnrx-5133, VNRX-5133, Vnrx5133, TANIBORBACTAM

Parent form; salt/anhydrous children: CHEMBL4594291

Patent coverage: 46 distinct patent families (112 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
bacterial infectious disease	1	MONDO:0005113	EFO:0000771

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE1	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02955459	PHASE1	COMPLETED	VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
NCT03332732	PHASE1	COMPLETED	VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers
NCT03690362	PHASE1	COMPLETED	VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
NCT03870490	PHASE1	COMPLETED	Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).